KRAS and lung carcinoma: This model and the GEM model from which the KP mutant cell lines were originally derived [19] closely recapitulate the progression of human lung cancer disease, with development of metastatic lesions throughout the body, as well as heterogeneity of immune infiltrate and response to immunotherapy agents [19,20,21,22,29]; thus, the similarity to KRAS-driven human lung cancer validates the use of these models to address specific immune-related questions, as well as to perform mechanistic and therapeutic studies.